Vimarsana
Biggest News Aggregation in the World

Page 7 - Time Dynamix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Time Dynamix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Time Dynamix Today - Breaking & Trending Today

Efficacy Expectations for Refractory Migraine Patients are Vital for Strong Uptake of Impel's Trudhesa, Spherix Reports - Vimarsana News

Efficacy Expectations for Refractory Migraine Patients are Vital for Strong Uptake of Impel's Trudhesa, Spherix Reports

/PRNewswire/ -- Impel's new entrant into the acute migraine landscape, the dihydroergotamine mesylate (DHE) nasal spray, Trudhesa, is off to a somewhat light...

Could Opportunity for Takeda's Subcutaneous Entyvio Diminish by the Time It Reaches Its Now Projected 2023 US Approval? Spherix Investigates - Vimarsana News

Could Opportunity for Takeda's Subcutaneous Entyvio Diminish by the Time It Reaches Its Now Projected 2023 US Approval? Spherix Investigates

/PRNewswire/ -- In their most recent earnings call on October 29, 2021, Takeda revealed that discussions with the FDA have led to a potential approval for...

Renal Anemia Market Revs Up in Europe With the Launch of FibroGen Inc's/Astellas Pharma's EVRENZO (Roxadustat), Spherix Global Insights Reports - Vimarsana News

Renal Anemia Market Revs Up in Europe With the Launch of FibroGen Inc's/Astellas Pharma's EVRENZO (Roxadustat), Spherix Global Insights Reports

/PRNewswire/ -- For decades, nephrologists across the globe have prescribed erythropoietin stimulating agents (ESAs), such as Amgen's Aranesp, Roche's Mircera,...

Renal Anemia Market Revs Up in Europe With the Launch of FibroGen Inc's/Astellas Pharma's EVRENZO (Roxadustat), Spherix Global Insights Reports - Vimarsana News

Renal Anemia Market Revs Up in Europe With the Launch of FibroGen Inc's/Astellas Pharma's EVRENZO (Roxadustat), Spherix Global Insights Reports

/PRNewswire/ -- For decades, nephrologists across the globe have prescribed erythropoietin stimulating agents (ESAs), such as Amgen's Aranesp, Roche's Mircera,...

Bristol Myers Squibb's Zeposia Launch Trajectories Diverge in Germany and the UK Following Negative NICE Decision; Janssen's Ponvory Could Likewise Stumble, According to Spherix Global Insights - Vimarsana News

Bristol Myers Squibb's Zeposia Launch Trajectories Diverge in Germany and the UK Following Negative NICE Decision; Janssen's Ponvory Could Likewise Stumble, According to Spherix Global Insights

/PRNewswire/ -- Following the May 2020 European Medicines Agency (EMA) approval of Bristol Myers Squibb's Zeposia and the May 2021 approval of Janssen's...